January 23, 2026
1 min read

ST Pharm inks $56M deal to produce API for a US biotech

ST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in a regulatory filing.

Leave a Reply

Your email address will not be published.

Previous Story

Answering Your Questions as RFK Jr. Promotes New Food Pyramid and Dietary Guidelines

Next Story

New state committee begins work to develop nutrition guidelines, education requirements for Texans

Previous Story

Answering Your Questions as RFK Jr. Promotes New Food Pyramid and Dietary Guidelines

Next Story

New state committee begins work to develop nutrition guidelines, education requirements for Texans

Latest from Blog

Go toTop